combine@alvar.ug

Antiretroviral therapy initiation within seven days of enrolment: outcomes and time to undetectable viral load among children at an urban HIV clinic in Uganda

Antiretroviral therapy initiation within seven days of enrolment: outcomes and time to undetectable viral load among children at an urban HIV clinic in Uganda

Show simple record

dc.contributor.author Ssebunya, Rogers
dc.contributor.author Wanyenze, Rhoda K.
dc.contributor.author Lukolyo, Heather
dc.contributor.author Mutto, Milton
dc.contributor.author Kisitu, Grace
dc.contributor.author Amuge, Pauline
dc.contributor.author Maganda, Albert
dc.contributor.author Kekitiinwa, Adeodata
dc.date.accessioned 2021-01-01T21:58:19Z
dc.date.available 2021-01-01T21:58:19Z
dc.date.issued 2017
dc.identifier.issn 1471-2334
dc.identifier.uri http://combine.alvar.ug/handle/1/48263
dc.description.abstract Background: Viral suppression is a critical indicator of HIV treatment success. In the era of test-and-start, little is known about treatment outcomes and time to undetectable viral loads. This study compares treatment outcomes, median times to achieve undetectable viral loads and its predictors under different antiretroviral (ART) treatment initiation schedules (i.e. within seven days of enrolment or later). Methods: A retrospective cohort of 367 patients < 18 years who enrolled in care between January 2010 and December 2015 with a baseline viral load of > 5000 copies/ml were followed up for 60 months. Undetectable viral load measurements were based on both Roche (< 20copies/ml) and Abbot (< 75copies/ml). Clinical treatment outcomes were compared using chi-squared test. Survival experiences between the two cohorts were assessed through incidence rates and Kaplan Meier curves. A cox model with competing risks was used to assess predictors for time to undetectable viral load. Results: Of the 367 patients, 180 (49.1%) initiated ART within seven days from enrolment, 192 (52.3%) attained undetectable viral load of which 133 (69.3%) were children below six years and 101 (52.6%) were females. Among those who initiated ART within seven days 15 (8.3%) died and 6 (3.3%) were lost to follow-up compared to 27 (14. 4%) and 16 (8.6%) respectively in the later initiators. The median time to undetectable viral load was 24.9 months (95% CI: 19.7, 28.5) among early ART initiators and 38.5 months (95% CI: 31.1, 44.5) among those initiating beyond seven days. There was a significant difference in failure estimates between those initiating within seven and those that deferred (log rank, p = 0.001). Significant predictors for time to undetectable viral load were; starting ART within seven days (SHR = 2.02, 95% CI: 1.24, 3.28), baseline WHO stage I or II (SHR = 1.59, 95% CI: 1.06, 2.28), inconsistent adherence on three consecutive clinic visits (SHR = 0.44, 95% CI: 0.28, 0.67), and baseline weight (SRH = 1.04, 95% CI: 1.01, 1.07). Conclusion: Prompt initiation of ART within the first week of enrolment is associated with better treatment outcomes. Early timing, baseline WHO clinical stage and adherence rates should be major considerations while managing HIV among children.
dc.language English
dc.publisher BIOMED CENTRAL LTD
dc.relation.ispartof BMC Infectious Diseases
dc.subject Hiv
dc.subject Undetectable Viral Load
dc.subject Antiretroviral Therapy
dc.subject Outcomes
dc.subject Timing
dc.title Antiretroviral therapy initiation within seven days of enrolment: outcomes and time to undetectable viral load among children at an urban HIV clinic in Uganda
dc.type Article
dc.identifier.isi 000403621900005
dc.identifier.doi 10.1186/s12879-017-2550-2
dc.identifier.pmid 28629459
dc.publisher.city LONDON
dc.publisher.address 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
dc.identifier.volume 17
dc.subject.wc Infectious Diseases
dc.subject.sc Infectious Diseases
dc.description.oa DOAJ Gold
dc.description.oa Green Published
dc.description.pages 8
dc.subject.kwp South-Africa
dc.subject.kwp Transmission Risk
dc.subject.kwp United-States
dc.subject.kwp Mortality
dc.subject.kwp Infection
dc.subject.kwp Adherence
dc.subject.kwp Trials
dc.subject.kwp Haart
dc.subject.kwp Impact
dc.subject.kwp Rna
dc.identifier.articleno 439
dc.description.affiliation Mulago Hosp Complex, Baylor Coll Med Childrens Fdn, POB 72052, Kampala, Uganda
dc.description.affiliation Makerere Univ, Coll Hlth Sci, Sch Publ Hlth, POB 7072, Kampala, Uganda
dc.description.email rssebunya@baylor-uganda.org
dc.description.corr Ssebunya, R (corresponding author), Mulago Hosp Complex, Baylor Coll Med Childrens Fdn, POB 72052, Kampala, Uganda.
dc.description.orcid Haq, Heather/0000-0003-4710-9911
dc.description.orcid Amuge, Pauline/0000-0001-5264-1916


This record appears in the collections of the following institution(s)

Show simple record

Search Entire Database


Browse

My Account